Hemogenyx Pharmaceuticals Plc
HEMO.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | – | £14,193 | £15,704 | £27,038 |
| - Cash | £227 | £159 | £1,643 | £1,248 |
| + Debt | £1,790 | £2,623 | £2,784 | £2,946 |
| Enterprise Value | – | £16,657 | £16,846 | £28,736 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Gross Profit | -£314 | -£318 | -£643 | -£326 |
| % Margin | – | – | – | – |
| EBITDA | -£4,573 | -£2,363 | -£4,704 | -£1,893 |
| % Margin | – | – | – | – |
| Net Income | -£5,004 | -£2,806 | -£3 | -£2,370 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.42 | -0.8 | -0.001 | -0.81 |
| % Growth | -77.5% | -88,788.9% | 99.9% | – |
| Operating Cash Flow | -£3,783 | -£1,783 | -£2 | -£2,775 |
| Capital Expenditures | -£4 | -£13 | £0 | -£104 |
| Free Cash Flow | -£3,787 | -£1,797 | -£2 | -£2,879 |